Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as a sterile powder for intravenous use. It treats certain advanced cancers in adult patients, most commonly metastatic colorectal cancer and relapsed small cell lung cancer. GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Kabi is employed in oncology regimens that target rapidly dividing tumor cells. - Metastatic colorectal cancer: improves survival when used in combination chemotherapy protocols. - Relapsed small cell lung cancer: provides disease control as a second‑line option. - Advanced gastrointestinal cancers: contributes to tumor reduction as part of multi‑agent therapy.

Irinotecan Kabi may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, a medical emergency. - Severe colitis: life‑threatening inflammation of the colon. - Cholinergic syndrome: sweating, salivation, and bradycardia. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes or jaundice. - Thromboembolic events: blood clots in veins or arteries.

Before initiating therapy with Irinotecan Kabi, several safety considerations are essential. - Dose adjustment: modify dosing in patients with hepatic impairment to avoid excess exposure. - Monitor blood counts: perform regular CBC tests to detect neutropenia early. - Assess renal function: adjust if severe renal dysfunction is present. - Avoid strong CYP3A4 inhibitors: concurrent use may increase drug levels and toxicity. - Pregnancy: prescribe only when potential benefits justify potential fetal risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Kabi can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations. - UGT1A1 inhibitors (e.g., atazanavir): increase risk of severe neutropenia. - Concurrent myelosuppressive agents: amplify bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.